Figure 5
Erlotinib upregulated FoxO1 expression through downregulation of miR-9.
(A) A549 cells were treated with or without erlotinib for 72 h and subjected to qRT-PCR assay. (B) A549 cells were treated with erlotinib in different concentrations for different times as indicated and subjected to western blot analysis. (C) A549 cells were transfected with miR-9 mimic and its control for 24 h, then treated with 10 μmol/L erlotinib for another 48 h. The whole-cell lysates were purified and subjected to western blot analysis. Fold change of each treatment vs. control was calculated after quantification and presented under each blot. (D) A549 cells in 96-well plates were infected with adenovirus encoding an active form of FoxO1 (Ad-CA) or its control (Ad-Ctrl), then treated with or without erlotinib for 3 days and subjected to SRB assay. Columns, means of three replicate determinations; points, means of four replicate determinations; bars, SD. *P < 0.05. The data are representatives of three independent experiments.
